Moberg Pharma increases full year net profit
February 14, 2017Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
The company said that fourth quarter net profit before tax was positive, but the net profit after tax was SEK -2.5 million (€264.000).
The acquisition of Dermoplast Prestige Brands (U.S.) in December, totalled $88 million. The CEO Peter Wolpert, said that Dermoplast is expected to become the company’s second largest brand, which will contribute to sales and profitability from in the U.S.
“We increased the market share for our lead brand Kerasal Nail® to record-levels in the U.S. and progressed MOB-015 to gain regulatory approval to start Phase 3 as well as initiated patient enrolment. As for Q4, we delivered strong growth in sales and tripled EBITDA fueled by recent acquisitions,” said Wolpert.
